Loading...
The Firm and the FDA: McKinsey and Company's Conflicts of Interest at the Heart of the Opioid Epidemic
House Committee on Oversight and Reform
House Committee on Oversight and Reform
Abstract
The House Committee on Oversight and Government Reform investigates McKinsey & Company's consulting services for opioid and pharmaceutical companies, revealing significant conflicts of interest. McKinsey advised opioid manufacturers on influencing FDA regulatory decisions while simultaneously consulting for federal agencies regulating the opioid market. The investigation uncovered instances of McKinsey utilizing its government connections to solicit private sector business and attempting to influence public health officials, including providing advice to the Trump Administration. McKinsey failed to disclose these conflicts of interest to the FDA and discussed deleting documents related to its work for Purdue. Despite evidence suggesting McKinsey's involvement in the opioid epidemic, the company has not fully cooperated with the investigation.
Date
2022-04-13
Document Type
House Majority Staff Report
Serial Number
Document Length
53 pages
Congress
117
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
324: Medical Liability, Fraud and Abuse